Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sedana Medical AB ( (SE:SEDANA) ) has provided an update.
Sedana Medical has appointed experienced finance executive Mikael Haag as its new Chief Financial Officer and member of the Executive Management Team, with him set to assume the role no later than July 2026, while current CFO Johan Spetz will stay on until June 2026 to ensure a smooth handover. The hire underscores Sedana Medical’s focus on strengthening its financial leadership to support expansion of its profitable European business and to build out a significant presence in the United States, leveraging Haag’s track record in scaling growth companies and his experience in the US market to drive continued growth and long-term value creation.
The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK10.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.
More about Sedana Medical AB
Sedana Medical AB is a Stockholm-listed medtech and pharmaceutical company specializing in inhaled sedation for mechanically ventilated intensive care patients. Combining its Sedaconda ACD medical device with the Sedaconda (isoflurane) pharmaceutical, the company targets improved patient outcomes in ICUs and distributes its products through a mix of direct sales in key European markets and external distributors across Europe, Asia, Australia, Canada, and South- and Central America.
Average Trading Volume: 163,481
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.06B
See more data about SEDANA stock on TipRanks’ Stock Analysis page.